U.S. Biotech Stock News

American Healthcare REIT recently reported second quarter 2025 earnings, highlighted by a year-over-year increase in net income and a raised full-year guidance for both net income per diluted share and same-store net operating income growth. The company also announced a $1 billion follow-on equity offering and is focusing on expanding its portfolio through more than $300 million in new acquisition opportunities, particularly in high-quality long-term care assets. We’ll explore how the...

Thinking about what to do with United Airlines Holdings stock right now? You are not alone. With the ticker UAL making eye-catching moves lately, investors are watching closely to see if the recent run has legs or if the ride is just beginning to hit turbulence. Let us talk numbers for a moment. Over the past three months, UAL has climbed more than 31%, and in the last year, total returns have soared nearly 138%. While some of that lift has come from broad travel demand bouncing back, there...

ZTO Express (Cayman) ( NYSE:ZTO ) Second Quarter 2025 Results Key Financial Results Revenue: CN¥11.8b (up 10% from 2Q...

H World Group Limited announced past second quarter earnings with revenue of CNY 6.43 billion, increased net income, and declared an interim cash dividend for 2025, alongside issuing third quarter guidance projecting revenue growth of up to 6% year-on-year. An important insight is the company's focus on manachised and franchised operations, expected to deliver double-digit revenue growth, highlighting a structural shift in its business model toward asset-light expansion. Now, we'll explore...

Earlier in August 2025, Waste Management reached all-time highs amid increased institutional investor interest, but concerns surfaced over insider selling and elevated valuations not aligned with its slower growth and balance sheet limitations. An interesting takeaway is that despite its strong institutional following, signals such as recent insider selling and contracting free cash flow have prompted analysts to question the foundation of its current premium valuation. We'll examine how...

If you’re eyeing General Motors stock and wondering whether now is the moment to get in, you’re not alone. GM has been on a steady climb that’s turning heads, up over 23% in the past year and nearly double over the last five. Recent weeks saw even more momentum, with the stock rising more than 15% in the past 90 days and almost 7% in the last month. That kind of move usually signals that something interesting is happening, whether it reflects confidence in long-term growth or a shift in how...

Trying to figure out what to do with your Lowe's Companies shares or considering jumping in? You are definitely not alone right now. With NYSE:LOW stock closing recently at $257.14, investors are looking for clues after a string of steady gains. Over the last month alone, Lowe's is up 16.4%, with a 14.9% bump over the last three months, and a remarkable 65.2% gain if you zoom out to the five-year timeframe. The company has grown annual revenue and net income recently, helping support those...

ABNB Federal Credit Union recently announced its partnership with Upstart Holdings to offer personal loans, joining the Upstart Referral Network in May 2025 and enabling a seamless digital loan experience for qualified applicants. This collaboration highlights Upstart's expanding reach in the credit union sector, facilitating more efficient lending and broader consumer access to its AI-driven loan platform. We'll assess how Upstart's successful US$600 million convertible note offering...

Earlier this month, Mercury Insurance introduced an enhanced personal umbrella insurance policy in Florida, providing expanded liability coverage including uninsured motorist protection and discounts for accident-free customers, with rates starting just over $1 a day. This launch responds directly to the increasing number of home and auto liability injury claims in Florida that exceed standard policy limits, marking the company's seventh state rollout for this product. We'll assess how the...

Disc Medicine, Inc. recently announced its financial results for the second quarter and first half of 2025, reporting a net loss of US$55.25 million for the quarter and US$89.33 million for the six-month period, both higher than the same periods last year. The widening losses highlight increased spending and may prompt questions among investors regarding the company’s path to profitability and resource allocation. We’ll now explore how Disc Medicine’s larger net loss shapes the company’s...

McCormick has recently expanded its lineup of limited-edition Finishing Sugars for fall and winter, introducing three new fall flavors and two new winter varieties alongside returning favorites, available both online and at retailers nationwide. Building on strong consumer demand from prior seasonal launches, the new and returning Finishing Sugars highlight McCormick’s ability to tap into seasonal trends and connect with customers seeking nostalgia and versatility in their culinary...

If you have been eyeing Broadcom’s stock lately, you are definitely not alone. The past year has been a whirlwind for AVGO, with the share price up more than 77% over the last twelve months. Even looking back over a longer stretch, it is hard not to be impressed: over the last five years, Broadcom’s total return has soared more than 860%. This kind of performance captures investors’ attention and prompts some big questions. Has the market gotten ahead of itself, or is there still value left...

It’s not every day that Cincinnati Financial (CINF) pops up on investors’ radars without a specific headline or major event driving discussion. That is exactly what is happening now, as a small uptick in the stock’s price has led some to wonder if this subtle move signals a turning point. For anyone trying to decide whether to hold, buy, or simply watch from the sidelines, even minor price shifts can open the door to bigger questions about what comes next. Looking at the bigger picture,...

OPKO Health recently advanced its Phase 1 Epstein-Barr virus vaccine trial and presented encouraging data for its oral GLP-1/glucagon dual agonist for obesity and MASH at ENDO 2025, while also announcing a plan to sell BioReference oncology and clinical testing assets to Labcorp to concentrate on its core businesses. This combination of clinical progress and repositioning initiatives highlights OPKO’s sharpened focus on developing high-impact treatments and strengthening its diagnostics...

In August 2025, AXIS Capital Holdings announced the appointment of Matthew Kirk as its next Chief Financial Officer, launched the AXIS Capacity Solutions business unit, and named David Murie as its head as part of a planned leadership transition and business expansion. These developments highlight AXIS’s emphasis on strengthening executive leadership and expanding specialty capacity solutions to capture growth opportunities in the evolving insurance market. We'll now examine how the...

Are you wondering what to do with Trimble stock right now? You are not alone. Whether you have been holding on for the long haul or you are considering dipping your toe in for the first time, Trimble’s recent performance certainly warrants a closer look. The stock has done some impressive climbing over the past year, gaining 42% in total return and even notching a 15% boost year-to-date. Granted, the last week has seen a slight pullback of about 5%, but that has not dimmed the bigger picture...

NYSE:IBTA 1 Year Share Price vs Fair Value Explore Ibotta's Fair Values from the Community and select yours Despite...

If you have been watching IQVIA Holdings, you are probably asking the same questions as many investors right now. Is this the moment to buy in, stay put, or wait until things cool off? IQVIA’s stock has had a dynamic run lately, which always gets attention when considering value and risk. Over the past month, IQVIA’s share price shot up by more than 20%, adding onto an impressive 39% total return over the last three months. Yet, when you zoom out, the picture is less rosy, with one-year...

Earlier this month, Enovix announced the opening of an 18,000-square-foot R&D Center of Excellence in Hyderabad, India, dedicated to accelerating its next-generation AI-2 battery platform with a 40-person team of engineers and scientists. This global collaboration is designed to substantially reduce product development timelines by uniting advanced battery modeling, materials science, and rapid prototyping across multiple international sites. We'll explore how the launch of the Hyderabad R&D...

The recent dip in MARA Holdings (MARA) may be giving investors pause, especially as crypto and blockchain-related stocks navigate ongoing uncertainty. Shares are down about 18% over the past month, following a bumpy year that has left many wondering if the market's risk appetite toward digital asset exposure is waning or simply recalibrating. With business fundamentals like revenue up 19% but net income showing a steep annual decline, the contrasting signals leave plenty of room for...

NasdaqGM:AURA 1 Year Share Price vs Fair Value Explore Aura Biosciences's Fair Values from the Community and select...

The recent dip in CSX (CSX) stock has caught the eye of many investors wondering if there is more to the story. With shares falling by over 1% in the last session, some are asking whether this movement signals new risk for the railway giant, or if it is a routine bout of volatility. The change is not tied to any major announcement or headline, making the situation even more interesting for those evaluating potential entry points. Over the past year, CSX has delivered moderate gains, posting...

Agnico Eagle Mines recently reported strong Q2 2025 results, achieving higher adjusted net income and free cash flow while reaffirming its full-year production guidance and continuing active share buybacks and dividend payments. A key insight from this report is that the company’s proactive focus on operational execution, balance sheet strength, and shareholder returns comes amid favorable gold prices and ongoing reinvestment in major growth projects. Next, we’ll assess how Agnico Eagle...

Earlier this week, Axsome Therapeutics announced it received a Paragraph IV Certification Notice from Apotex related to a proposed generic version of Symbravo®, following Apotex’s Abbreviated New Drug Application filing with the FDA. This notice signals a potential challenge to Symbravo®’s intellectual property, raising questions for Axsome’s future market exclusivity and revenue streams. We’ll examine how this potential generic threat to Symbravo® could alter Axsome’s longer-term portfolio...